The original study, published in August 2026, was an exploratory translational proteomics investigation. Rather than examining blood, the researchers turned to cerebrospinal fluid, the clear liquid that bathes the brain and spinal cord and that often reflects biochemical events happening inside the skull far more faithfully than peripheral blood does. Using proteomic analysis, they identified hemopexin as a molecule of interest, reporting that its levels in cerebrospinal fluid appeared to track with the later development of secondary sepsis and with in-hospital outcomes in patients who had suffered a spontaneous intracerebral hemorrhage, a devastating form of stroke caused by a ruptured blood vessel inside the brain.

Hemopexin is not an arbitrary candidate. It is the body’s highest-affinity binder of free heme, the iron-containing molecule at the heart of hemoglobin. When blood cells rupture, as they do in large quantities after an intracerebral hemorrhage, heme is released into surrounding tissues and fluids. Free heme is a double-edged molecule: it is essential for life, but in its unbound form it catalyzes the formation of reactive oxygen species, damages cell membranes, and amplifies inflammation. Hemopexin acts as a molecular sponge, sequestering heme and escorting it to receptors that clear it from the extracellular space. In the brain, where hemorrhage floods tissue with hemoglobin breakdown products, hemopexin sits at the front line of the body’s attempt to contain the damage.

That biology is precisely why the protein has attracted attention before. A 2018 study published in the Journal of Cerebral Blood Flow and Metabolism by Leclerc and colleagues reported that increased brain hemopexin levels improved outcomes after intracerebral hemorrhage in experimental models, supporting the idea that the protein is protective rather than merely a passive marker of bleeding. Against that backdrop, the new proteomic finding that cerebrospinal fluid hemopexin might signal something as seemingly distant as sepsis, a systemic infection-driven syndrome, was provocative. It suggested that the biochemical storm unleashed by brain injury and the immune collapse of sepsis might be connected through measurable molecular threads.

The letter to the editor, authored by Ahmed H and Niazi M and entitled Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage, challenged that interpretation. Letters of this kind are a standard mechanism of scientific self-correction: they allow outside experts to interrogate a study’s assumptions, methods, and conclusions in public. The correspondents appear to have questioned whether the hemopexin signal truly represents a sepsis-specific phenomenon, or whether it might instead reflect more general processes, such as the sheer volume of bleeding, blood-brain barrier disruption, or the intensity of the inflammatory response to the hemorrhage itself. That distinction matters enormously, because a biomarker that merely tracks injury severity would be far less useful for clinical decision-making than one that specifically predicts a treatable complication like infection.

In their formal response, published on October 6, 2026, Xie and colleagues defended their work while engaging with the critique. The response, prepared by the same team from the Department of Critical Care Medicine at Huashan Hospital, addressed the methodological concerns raised by the correspondents. Among the references cited in the exchange is a landmark methodological paper by Riley and colleagues in the British Medical Journal on calculating the sample size required for developing a clinical prediction model, a detail that signals the debate touched on the statistical foundations of biomarker research. Prediction models, unlike simple association studies, are intended to generate risk estimates for individual patients, and the field has learned through painful experience that models built on small samples with too many variables tend to fail when tested on new patients.

That concern is especially acute in sepsis research after intracerebral hemorrhage. Patients with brain bleeds are among the most vulnerable in the intensive care unit: they may be immobile, intubated, unable to protect their airways, and fitted with invasive devices, all of which raise infection risk. Detecting sepsis early in such patients is notoriously difficult because the classic signs, fever, elevated heart rate, abnormal white blood cell counts, can be produced by the brain injury itself. A 2025 multicenter retrospective study published in the Journal of Medical Internet Research by Liu and colleagues attempted to build an explainable prediction model for sepsis in patients with intracerebral hemorrhage, underscoring both the clinical demand for such tools and the methodological rigor required to build them credibly. Against this landscape, any proposed biomarker, particularly one drawn from an invasive fluid like cerebrospinal fluid, must clear a high evidentiary bar.

The Shanghai team’s response also reflects the realities of exploratory translational science. The original study was explicitly framed as exploratory, a word that carries weight in the biomarker literature. Exploratory proteomics studies generate hypotheses; they do not, on their own, establish clinical validity. The researchers acknowledged the preliminary nature of their findings while maintaining that hemopexin deserves continued investigation as a candidate marker. Their response, like the original study, was published without dedicated funding, and the authors declared no conflicts of interest. They also disclosed that ChatGPT was used solely for English language editing, with all authors reviewing and verifying the final content, a level of transparency about artificial intelligence use that has become increasingly expected in biomedical publishing.

What makes this exchange worth watching is what it reveals about the path from a proteomic discovery to a bedside test. For cerebrospinal fluid hemopexin to become a genuine clinical tool, several hurdles remain. The finding would need independent replication in larger, ideally multicenter cohorts. Researchers would need to demonstrate that hemopexin adds predictive value beyond existing clinical variables such as hemorrhage volume, location, Glasgow Coma Scale score, and standard inflammatory markers. They would need to establish whether serial measurements, rather than a single time point, improve prediction. And because lumbar puncture is invasive and not without risk in patients with mass lesions in the brain, the practical case for a cerebrospinal fluid marker would need to be compelling, or the signal would need to be mirrored in blood.

The deeper scientific question raised by the letter, whether hemopexin is a sepsis-specific signal or a general readout of injury and inflammation, is exactly the kind of question that rigorous debate is designed to resolve. If hemopexin turns out to be a broad marker of heme burden and barrier disruption, it may still be valuable, perhaps as an indicator of secondary brain injury. If it is genuinely specific to the transition toward systemic infection, it could open a window into the poorly understood mechanisms by which catastrophic brain injury destabilizes systemic immunity. Either answer would advance the field; the current exchange ensures the question is asked properly. For now, the verdict of the scientific process is still pending, and patients with intracerebral hemorrhage, who face sepsis as one of the most dangerous complications of their condition, await the larger studies that will determine whether this heme-scavenging protein can deliver on its early promise.

Subject of Research: Cerebrospinal fluid hemopexin as a candidate biomarker for secondary sepsis after spontaneous intracerebral hemorrhage

Article Title: Response to the Letter to the Editor Entitled “Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage” Regarding the Study “Cerebrospinal Fluid Hemopexin as a Candidate Biomarker for Secondary Sepsis and In-hospital Outcome After Spontaneous Intracerebral Hemorrhage: An Exploratory Translational Proteomics Study”

Article References: Xie, T., Feng, W., He, Y., Cao, Y., & Deng, S. (2026). Response to the Letter to the Editor Entitled “Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage” Regarding the Study “Cerebrospinal Fluid Hemopexin as a Candidate Biomarker for Secondary Sepsis and In-hospital Outcome After Spontaneous Intracerebral Hemorrhage: An Exploratory Translational Proteomics Study”. Neurocritical Care. https://doi.org/10.1007/s12028-026-02663-4

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02663-4

Keywords: hemopexin, cerebrospinal fluid, sepsis, intracerebral hemorrhage, biomarkers, proteomics, neurocritical care, heme, prediction models, inflammation, stroke, critical care

The original investigation, published in the journal Neurocritical Care by Xie and colleagues, set out to answer a deceptively simple question: can the protein composition of the fluid bathing the brain reveal which patients with intracerebral hemorrhage will go on to develop secondary sepsis during their hospital stay? Using an exploratory proteomics approach, the researchers examined cerebrospinal fluid samples and identified hemopexin as a candidate biomarker, one whose levels appeared to track both the emergence of sepsis and the overall in-hospital outcome. If the finding holds up in larger and more diverse cohorts, it could give clinicians a biochemical head start on a complication that is far easier to treat when caught early.

To understand why hemopexin makes biological sense as a player in this drama, it helps to know what the protein actually does. Hemopexin is a plasma glycoprotein produced mainly by the liver, and it binds free heme — the iron-containing prosthetic group of hemoglobin — with the highest affinity of any known protein. After an intracerebral hemorrhage, red blood cells that escape into brain tissue lyse and release hemoglobin and heme in large quantities. Free heme is not an innocent bystander; it is a potent pro-oxidant and pro-inflammatory molecule that catalyzes the formation of reactive oxygen species, damages the blood-brain barrier, and amplifies the very inflammatory cascades that can spiral into systemic illness. Hemopexin mops up this heme and shuttles it to the liver for degradation, acting as a critical line of defense against heme-driven toxicity.

Earlier experimental work had already hinted that hemopexin sits at the fulcrum of recovery after brain bleeds. A 2018 study published in the Journal of Cerebral Blood Flow and Metabolism reported that increased brain hemopexin levels improved outcomes after intracerebral hemorrhage in animal models, supporting the idea that the heme-scavenging system is not merely a passive witness to injury but an active participant in the brain’s response. Against that backdrop, the new finding that cerebrospinal fluid hemopexin might also serve as a sepsis-specific signal adds an intriguing systemic dimension: the same protein that protects the injured brain locally may also register, or even mediate, the body-wide inflammatory storm that accompanies sepsis.

The clinical stakes are considerable. Spontaneous intracerebral hemorrhage accounts for a substantial share of stroke worldwide and carries high mortality and disability rates, which is why the American Heart Association and American Stroke Association issued updated management guidelines in 2022 covering everything from blood pressure control to surgical intervention. Within this framework, post-hemorrhagic sepsis remains a stubborn problem: it prolongs intensive care stays, worsens functional outcomes, and complicates decisions about the withdrawal or escalation of care. Current detection relies on nonspecific markers such as fever, white blood cell counts, and inflammatory indices like procalcitonin and C-reactive protein, none of which are specific to the neurocritical population. A cerebrospinal fluid biomarker that rises ahead of overt sepsis could, in principle, reshape surveillance on the neuro-ICU.

Yet the path from an exploratory proteomics signal to a clinically trusted biomarker is littered with statistical pitfalls, and this is precisely where the new letter to the editor enters the story. Humaiz Ahmed and Mahroo Niazi of Karachi Medical and Dental College published a correspondence in Neurocritical Care engaging directly with the original study, and their critique centers on the statistical architecture of the biomarker analysis rather than on the underlying biology. Their concerns are grounded in two classic methodological references that have shaped how clinical prediction research is judged for decades.

The first is the influential 1996 simulation study by Peduzzi and colleagues on the number of events per variable in logistic regression analysis. That work established a widely cited rule of thumb: logistic regression models need roughly ten outcome events for every predictor variable to produce stable, unbiased estimates. When the number of events is small relative to the number of candidate predictors — a situation that arises almost inevitably in exploratory proteomics, where hundreds or thousands of proteins are screened in modest patient cohorts — the resulting models are prone to overfitting, inflated effect sizes, and poor performance when applied to new patients. Ahmed and Niazi invoke this principle to question whether the hemopexin-sepsis association, however biologically plausible, can be reliably estimated from the sample at hand.

The second pillar of their critique draws on the 2020 guidance by Riley and colleagues, published in the BMJ, on calculating the sample size required for developing a clinical prediction model. That framework argues that prediction model studies should be designed with a target sample size determined in advance, based on the number of candidate predictors, the expected outcome proportion, and the desired precision of key parameters — not simply on whatever cohort happens to be available. Applied to the hemopexin study, the implication is that an exploratory translational analysis, however carefully conducted, may not have been powered to deliver a prediction model that clinicians can trust at the bedside. The letter thus functions less as a demolition of the finding and more as a call for the rigorous, pre-specified validation work that biomarker science demands.

The debate also unfolds against a rapidly evolving backdrop of sepsis prediction in intracerebral hemorrhage. In 2025, a multicenter retrospective study published in the Journal of Medical Internet Research identified and validated an explainable prediction model for sepsis in patients with intracerebral hemorrhage, demonstrating growing interest in machine-learning and clinically interpretable tools for this exact problem. In such a competitive field, any new biomarker — whether a single protein like hemopexin or a composite score — will be judged not only on its biological story but on whether it adds predictive value beyond existing clinical variables, and whether it survives external validation in independent, multicenter cohorts. The correspondence from Ahmed and Niazi is, in effect, a reminder that the bar for that evidence is high and well defined.

What emerges from this exchange is a picture of science working as intended. The original proteomics study offers a biologically coherent candidate: a heme-scavenging protein whose cerebrospinal fluid levels could plausibly reflect both the severity of intracranial injury and the systemic inflammatory state that predisposes to sepsis. The letter to the editor subjects that candidate to the statistical scrutiny that separates promising signals from clinical tools, citing the events-per-variable literature and prediction model sample size guidance as the relevant standards. The study authors have published a response, keeping the dialogue open. For patients and clinicians, the takeaway is one of cautious optimism: hemopexin may yet earn a place in the neurocritical care toolkit, but it will have to pass through larger, prospectively designed validation studies before a cerebrospinal fluid measurement becomes a routine part of sepsis surveillance after brain hemorrhage. Until then, the molecule that ferries heme out of the injured brain remains one of the most interesting leads in a field where every early warning counts.

Subject of Research: Cerebrospinal fluid hemopexin as a candidate biomarker for secondary sepsis and in-hospital outcome after spontaneous intracerebral hemorrhage

Article Title: Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage

Article References: Ahmed, H., & Niazi, M. (2026). Cerebrospinal Fluid Hemopexin as a Sepsis-Specific Signal After Intracerebral Hemorrhage. Neurocritical Care. https://doi.org/10.1007/s12028-026-02664-3

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02664-3

Keywords: hemopexin, cerebrospinal fluid, intracerebral hemorrhage, sepsis, biomarkers, proteomics, neurocritical care, logistic regression, prediction models, heme scavenging, stroke, in-hospital outcome